Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950123-08-003041
Filing Date
2008-03-17
Accepted
2008-03-17 16:49:53
Documents
10
Period of Report
2007-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K y50379e10vk.htm 10-K 788274
2 EX-10.28: EMPLOYMENT AGREEMENT--DROPPERT y50379exv10w28.htm EX-10.28 44552
3 EX-10.32: LEASE AGREEMENT y50379exv10w32.htm EX-10.32 264748
4 EX-10.33: FIRST AMENDMENT TO LEASE y50379exv10w33.htm EX-10.33 25913
5 EX-10.34: AMENDMENT TO CONSTRUCTION AGREEMENT y50379exv10w34.htm EX-10.34 20252
6 EX-23.1: CONSENT OF KOST, FORER, GABBAY & KASIERER y50379exv23w1.htm EX-23.1 2458
7 EX-31.1: CERTIFICATION y50379exv31w1.htm EX-31.1 8005
8 EX-31.2: CERTIFICATION y50379exv31w2.htm EX-31.2 8251
9 EX-32: CERTIFICATION y50379exv32.htm EX-32 4106
10 GRAPHIC y50379y5037901.gif GRAPHIC 560
  Complete submission text file 0000950123-08-003041.txt   1168914
Mailing Address 630 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10111
Business Address 630 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10111 (212) 887-6500
Omrix Biopharmaceuticals, Inc. (Filer) CIK: 0001349426 (see all company filings)

EIN.: 522147005 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-51905 | Film No.: 08693506
SIC: 2836 Biological Products, (No Diagnostic Substances)